The Env protein (heterodimer made up of gp41 and gp120, natively present in trimers) is the sole target of HIV neutralizing antibodies. to these systems, more diseases will become resolved in the 21st century by novel preventative and restorative vaccines. for vaccine production, and the first-generation HBV vaccine consisted of purified HBV surface antigen from your blood of infected THIP donors. Progress in molecular biology allowed the improvement of the vaccine against HBV and, more recently, the development of a new vaccine avoiding HPV. Both vaccines are made of purified recombinant protein antigens that form a non-infectious viral-like particle (VLP). In the last decade, progress in genomics has also contributed to vaccine development. Unlike the additional meningococci, type B (MenB) is definitely covered by a capsular polysaccharide that is much like polysaccharide present in human tissues and therefore poorly immunogenic. As such, the MenB capsular polysaccharide cannot be used in a glycoconjugate vaccine, unlike what was efficiently carried out for types A, C, W, and Y (Pace, 2009). Making a vaccine based on recombinant proteins was also demanding because of the intense antigenic variation seen in circulating MenB strains. The problem was solved through a rational selection of candidate antigens based on genomic info, called reverse vaccinology (Pizza as the breakthrough of the year for 2013 (Couzin-Frankel, 2013). Open in a separate window Number 1 Major milestones in the historic path of the development of vaccinology and vaccine designA method for avoiding naturally acquired smallpox called variolation was found out in India before 1,000 A.D. and was in use also in China and Western Asia. This method, which consisted of the inoculation of pustule material from smallpox-infected individuals to healthy individuals, was launched in Europe in 1,721 by Woman Mary Wortley Montagu. The first real vaccination practice was launched when Edward Jenner used pustule material from humans infected by cowpox to protect against smallpox. Table 1 Licensed vaccines are grouped into seven classes based on the method of production: live attenuated, killed whole organisms, toxoids/proteins, polysaccharides, glycoconjugates, recombinant, and customized blood cell re-infusion B; pneumococcus (7, 10, and 13 valent), meningococcus C, meningococcus ACWYpassage, chemically, genetically, or additional means Inactivateda killed infectious organism: whole organisms may be inactivated by chemical, thermal, or additional means Subunit vaccinesvaccines derived from components of the disease-causing organism, such as specific proteins and polysaccharides Polysaccharide vaccinesvaccine derived from the complex sugars capsular polysaccharide that covers the surface of encapsulated bacteria Conjugate vaccinevaccines derived from the covalent linkage (conjugation) of polysaccharides to a carrier protein for enhanced immunogenicity Combination vaccinesvaccines against different disease-causing organisms combined into one THIP formulation for a unique immunization Synthetic vaccinesvaccines based on synthetic components such as nucleic acids or synthetic peptides, polysaccharides, or antigens Recombinantderived from the use of recombinant DNA technology Reverse vaccinologya method of producing a vaccine by 1st studying the genomic info of the organism (and screening of those candidates and selection for vaccine development Serotypethe type of a microorganism determined by its constituent antigens Serogroupsa group of serotypes having one or more antigens in common Neutralizing antibodiesAn antibody that reduces or abolishes some biological activity of a soluble antigen or of a living microorganism Opsonizing antibodiesAn antibody that causes bacteria or additional foreign cells to become more susceptible to the action of phagocytes Nosocomially acquired antibiotic-resistant bacteriahospitally acquired bacteria that are no longer susceptible to treatment with antibiotics In summary, the application of innovative systems in the last century offers allowed for the development of novel vaccines targeting fresh diseases or new target populations. In the next paragraphs of this review, we will focus on vaccines 4933436N17Rik for the prevention of infectious diseases, give an overview of recent medical tests of some important vaccine candidates in development, and discuss which target populations are not properly safeguarded by vaccines. Finally, we will assess THIP the novel immunization systems that can be developed today to address the medical needs of the 21st century (GIVS 2006C2015 at http://www.who.int/immunization/givs/en/). Medical needs and challenges Program immunization programs protect most of the world’s children from a number of infectious diseases that previously claimed millions of lives each year. For travelers, vaccination offers the possibility of avoiding a number of infectious diseases that may be experienced abroad. However, acceptable vaccines have not yet been developed against several widespread and life-threatening infections. Human immunodeficiency virus (HIV) affects more than 30 million people worldwide (UNIAIDS Global Report at http://www.unaids.org/en), while malaria and tuberculosis kill almost 3.